The Cancer-Immunity Cycle: Methods, Challenges, and Opportunities
About this Series
Recent advances in cancer immunotherapy research have paved the way for the development of new clinical treatment options. Understanding the cancer immunity cycle as a whole can facilitate the identification of new putative immunotherapeutic targets, mechanisms, and strategies towards a more durable response. To be effective, treatments must retain activity despite negative feedback mechanisms, necessitating in the consideration of each step in the cycle. Fortunately, a number of innovative, advanced, and efficient techniques are now available to enable preclinical screening of new treatment approaches.

In this series, experts will review how cancer immunotherapy is studied along each step of the cancer immunity cycle, including an overview of technologies, techniques, challenges, and emerging research questions to be addressed. A number of innovative and advanced techniques to enable preclinical screening of new treatment approaches will be discussed as well as how to select appropriate in vitro methods for immunotherapeutic evaluation within the framework of the cancer immunity cycle.
Webinars in this Series
  • Thu Nov 3 at 11:00AM - 12:00PM (ET)
    Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
    Thursday, November 3, 2022 · 11:00 AM EDT
    In this webinar, Dr. Rajendra Kumari and Dr. Gera Goverse will discuss the basics of immuno-oncology and how cancer immunotherapies are studied along each step of the cancer immunity cycle. They will provide an overview of in vivo, ex vivo and in vitro assays available, including both traditional as well as novel assays. They will also describe the importance and applications of several technology platforms including flow cytometry, histology, single cell analysis, cytokine profiling, T cell cytotoxicity, and high content imaging, and highlight relevant examples from the literature that used them.

    Key learning objectives:
    • - What is the cancer immunity cycle? How are the steps of the cycle regulated, and which steps are potential targets for immunotherapeutics?
    • - Understand the advantages and limitations of 2D, 3D, in vivo, and ex vivo models
    • - Applications of high-content imaging and why HCI analysis is so valuable for preclinical immuno-oncology research
  • Thu Dec 1 at 11:00AM - 12:00PM (ET)
    Targeting T Cells Within the Cancer Immunity Cycle
    Thursday, December 1, 2022 · 11:00 AM EST
    In the second webinar in this series, Dr. Marrit Putker, Dr. Pirouz Daftarian and Dr. Saskia De Man focus on the impact of T cell-directed immunotherapy on the cancer-immunity cycle. Mechanisms and targets capable of modulating and enhancing T cell activity will be presented, including the application of relevant methods such as organoid models and co-cultures, and the integration of High Content Imaging (HCI).

    Key learning objectives include:
    • - Identify the right assays targeting T cell biology with immunotherapeutics at the different steps of the cancer immunity cycle such as T cell activation, migration, infiltration, and tumor killing
    • - Application of a unique 3D organoid platform with immune cell co-culture for immunotherapy studies and the advantages of autologous systems
    • - Integration of high content imaging-based screening to evaluate drug responses in 3D assays
    • - Modeling T cell exhaustion in a more physiologically relevant in vitro human system for the function-based screening of successful immunotherapeutics that delay or reverse this roadblock in antigen-specific T cell activity/proliferation
  • Thu Jan 26 at 11:00AM - 12:00PM (ET)
    Analyzing the Suppressive TME in in Vitro Based Assays
    Thursday, January 26, 2023 · 11:00 AM EST
    In the third webinar in this series, Dr Nataliia Beztsinna and Dr. Marten Hornsveld will describe the role of tumor microenvironment (TME) compartments in clinical responses, as well as ex vivo patient-derived tissue technologies capable of maintaining the native TME for pre-clinical testing. Complex in vitro models with the use of human stromal and immune co-cultures will be discussed, together with the advantages of HCI to quantify intact tumor biology.

    Key Topics Include:
    • - Examine the key components of the TME that affect immunotherapy responses
    • - Discuss the main approaches to analyse the TME composition and the differences between ‘hot’ and ‘cold’ solid tumors
    • - Identify ex vivo assays capable of maintaining native human TME
    • - Discuss the advantages of high content imaging assay on fresh patient tissue in 3D for deciphering complex immuno-oncology drug responses
    • - Comparison between in vitro based assays containing native TME or reconstituted TME
    • - How myeloid cells in the TME affect tumors and methods to study and target this compartment
    • - Advances in modelling the mesenchymal TME compartment in vitro and constructing pre-clinical mini-tumor platforms
  • Thu Mar 2 at 11:00AM - 12:00PM (ET)
    What's Next in Preclinical Cancer Immunotherapy Research?
    Thursday, March 2, 2023 · 11:00 AM EST
    The final webinar in this series will include a panel discussion of key topics in the field of cancer immunotherapy, including new and emerging methods, recent publications, and future directions. The links between preclinical research, in vivo studies, and biomarkers will be explored, as well as the unique advantages of Crown Bioscience and their service offerings.

    Key learning objectives:
    • - How our understanding of the cancer immunity cycle impacts cancer immunotherapy development
    • - Which new in vitro technologies provide more physiological and translatable drug responses
    • - Why HCI is providing deeper insights into drug responses
    • - What novel solutions are on the horizon to overcome the challenges of immunotherapeutic development
Sign up today!